A citation-based method for searching scientific literature

Gabriel Fernando Torres, Carlos Eduardo Bonilla, Giancarlo Buitrago, Oscar Arrieta, Umberto Malapelle, Christian Rolfo, Andrés F Cardona. Crit Rev Oncol Hematol 2021
Times Cited: 2







List of co-cited articles
1 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Next generation sequencing for liquid biopsy based testing in non-small cell lung cancer in 2021.
Pasquale Pisapia, José Luis Costa, Francesco Pepe, Gianluca Russo, Gianluca Gragnano, Alessandro Russo, Antonino Iaccarino, Diego de Miguel-Perez, Maria Josè Serrano, Valeria Denninghoff,[...]. Crit Rev Oncol Hematol 2021
12
100

Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study.
Wen-Zhao Zhong, Qun Wang, Wei-Min Mao, Song-Tao Xu, Lin Wu, Yi Shen, Yong-Yu Liu, Chun Chen, Ying Cheng, Lin Xu,[...]. Lancet Oncol 2018
299
50

Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study.
Glenwood D Goss, Chris O'Callaghan, Ian Lorimer, Ming-Sound Tsao, Gregory A Masters, James Jett, Martin J Edelman, Rogerio Lilenbaum, Hak Choy, Fadlo Khuri,[...]. J Clin Oncol 2013
238
50

Neoadjuvant osimertinib with/without chemotherapy versus chemotherapy alone for EGFR-mutated resectable non-small-cell lung cancer: NeoADAURA.
Masahiro Tsuboi, Walter Weder, Carles Escriu, Collin Blakely, Jianxing He, Sanja Dacic, Yasushi Yatabe, Lingmin Zeng, Andrew Walding, Jamie E Chaft. Future Oncol 2021
18
50

Screening for epidermal growth factor receptor mutations in lung cancer.
Rafael Rosell, Teresa Moran, Cristina Queralt, Rut Porta, Felipe Cardenal, Carlos Camps, Margarita Majem, Guillermo Lopez-Vivanco, Dolores Isla, Mariano Provencio,[...]. N Engl J Med 2009
50

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.
Yi-Long Wu, Caicun Zhou, Cheng-Ping Hu, Jifeng Feng, Shun Lu, Yunchao Huang, Wei Li, Mei Hou, Jian Hua Shi, Kye Young Lee,[...]. Lancet Oncol 2014
50

Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy.
Jacqueline V Aredo, Isa Mambetsariev, Jessica A Hellyer, Arya Amini, Joel W Neal, Sukhmani K Padda, Caroline E McCoach, Jonathan W Riess, Elwyn C Cabebe, Jarushka Naidoo,[...]. J Thorac Oncol 2021
39
50

Neoadjuvant EGFR-TKI Therapy for EGFR-Mutant NSCLC: A Systematic Review and Pooled Analysis of Five Prospective Clinical Trials.
Li Sun, Yi-Jia Guo, Jun Song, Yan-Ru Wang, Shu-Ling Zhang, Le-Tian Huang, Jian-Zhu Zhao, Wei Jing, Cheng-Bo Han, Jie-Tao Ma. Front Oncol 2021
21
50

Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC.
Suresh S Ramalingam, Johan Vansteenkiste, David Planchard, Byoung Chul Cho, Jhanelle E Gray, Yuichiro Ohe, Caicun Zhou, Thanyanan Reungwetwattana, Ying Cheng, Busyamas Chewaskulyong,[...]. N Engl J Med 2020
898
50

Gefitinib as neoadjuvant therapy for resectable stage II-IIIA non-small cell lung cancer: A phase II study.
Yang Zhang, Fangqiu Fu, Haichuan Hu, Shengping Wang, Yuan Li, Hong Hu, Haiquan Chen. J Thorac Cardiovasc Surg 2021
24
50



Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Treatment of Stage IIIA-N2 EGFR-Mutant Non-Small-Cell Lung Cancer (EMERGING-CTONG 1103): A Randomized Phase II Study.
Wen-Zhao Zhong, Ke-Neng Chen, Chun Chen, Chun-Dong Gu, Jun Wang, Xue-Ning Yang, Wei-Min Mao, Qun Wang, Gui-Bin Qiao, Ying Cheng,[...]. J Clin Oncol 2019
109
50

Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial.
Karen Kelly, Nasser K Altorki, Wilfried E E Eberhardt, Mary E R O'Brien, David R Spigel, Lucio Crinò, Chun-Ming Tsai, Joo-Hang Kim, Eun Kyung Cho, Philip C Hoffman,[...]. J Clin Oncol 2015
274
50

Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients' data.
Audrey Mauguen, Jean-Pierre Pignon, Sarah Burdett, Caroline Domerg, David Fisher, Rebecca Paulus, Samithra J Mandrekar, Chandra P Belani, Frances A Shepherd, Tim Eisen,[...]. Lancet Oncol 2013
152
50

Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer.
Yi-Long Wu, Masahiro Tsuboi, Jie He, Thomas John, Christian Grohe, Margarita Majem, Jonathan W Goldman, Konstantin Laktionov, Sang-We Kim, Terufumi Kato,[...]. N Engl J Med 2020
451
50

EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer.
Zhong-Yi Dong, Jia-Tao Zhang, Si-Yang Liu, Jian Su, Chao Zhang, Zhi Xie, Qing Zhou, Hai-Yan Tu, Chong-Rui Xu, Li-Xu Yan,[...]. Oncoimmunology 2017
213
50

Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN): a randomised, open-label, phase 2 trial.
Dongsheng Yue, Shidong Xu, Qun Wang, Xiaofei Li, Yi Shen, Heng Zhao, Chun Chen, Weimin Mao, Wei Liu, Junfeng Liu,[...]. Lancet Respir Med 2018
146
50

Modeling Clinical Responses to Targeted Therapies by Patient-Derived Organoids of Advanced Lung Adenocarcinoma.
Seok-Young Kim, Sang-Min Kim, Sumin Lim, Ji Yeon Lee, Su-Jin Choi, San-Duk Yang, Mi Ran Yun, Chang Gon Kim, Seo Rin Gu, Chaewon Park,[...]. Clin Cancer Res 2021
12
50

Trends in stage distribution for patients with non-small cell lung cancer: a National Cancer Database survey.
Daniel Morgensztern, Shean Huey Ng, Feng Gao, Ramaswamy Govindan. J Thorac Oncol 2010
353
50

Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.
Scott J Antonia, Augusto Villegas, Davey Daniel, David Vicente, Shuji Murakami, Rina Hui, Takashi Yokoi, Alberto Chiappori, Ki H Lee, Maike de Wit,[...]. N Engl J Med 2017
50

Efficacy of erlotinib as neoadjuvant regimen in EGFR-mutant locally advanced non-small cell lung cancer patients.
Liwen Xiong, Yuqing Lou, Hao Bai, Rong Li, Jinjing Xia, Wentao Fang, Jie Zhang, Han Han-Zhang, Analyn Lizaso, Bing Li,[...]. J Int Med Res 2020
13
50

Clonal Evolution and Heterogeneity of Osimertinib Acquired Resistance Mechanisms in EGFR Mutant Lung Cancer.
Nitin Roper, Anna-Leigh Brown, Jun S Wei, Svetlana Pack, Christopher Trindade, Chul Kim, Olivia Restifo, Shaojian Gao, Sivasish Sindiri, Farid Mehrabadi,[...]. Cell Rep Med 2020
45
50

Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC.
Scott J Antonia, Augusto Villegas, Davey Daniel, David Vicente, Shuji Murakami, Rina Hui, Takayasu Kurata, Alberto Chiappori, Ki H Lee, Maike de Wit,[...]. N Engl J Med 2018
50

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.
Thomas J Lynch, Daphne W Bell, Raffaella Sordella, Sarada Gurubhagavatula, Ross A Okimoto, Brian W Brannigan, Patricia L Harris, Sara M Haserlat, Jeffrey G Supko, Frank G Haluska,[...]. N Engl J Med 2004
50

Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group.
Jean-Pierre Pignon, Hélène Tribodet, Giorgio V Scagliotti, Jean-Yves Douillard, Frances A Shepherd, Richard J Stephens, Ariane Dunant, Valter Torri, Rafael Rosell, Lesley Seymour,[...]. J Clin Oncol 2008
50

Molecular characteristics predict clinical outcomes: prospective trial correlating response to the EGFR tyrosine kinase inhibitor gefitinib with the presence of sensitizing mutations in the tyrosine binding domain of the EGFR gene.
Naiyer A Rizvi, Valerie Rusch, William Pao, Jamie E Chaft, Marc Ladanyi, Vincent A Miller, Lee M Krug, Christopher G Azzoli, Manjit Bains, Robert Downey,[...]. Clin Cancer Res 2011
52
50

Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
P E Postmus, K M Kerr, M Oudkerk, S Senan, D A Waller, J Vansteenkiste, C Escriu, S Peters. Ann Oncol 2017
783
50

NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 2.2021.
David S Ettinger, Douglas E Wood, Dara L Aisner, Wallace Akerley, Jessica R Bauman, Ankit Bharat, Debora S Bruno, Joe Y Chang, Lucian R Chirieac, Thomas A D'Amico,[...]. J Natl Compr Canc Netw 2021
265
50

Phase II study of biomarker-guided neoadjuvant treatment strategy for IIIA-N2 non-small cell lung cancer based on epidermal growth factor receptor mutation status.
Wenzhao Zhong, Xuening Yang, Honghong Yan, Xuchao Zhang, Jian Su, Zhihong Chen, Riqiang Liao, Qiang Nie, Song Dong, Qing Zhou,[...]. J Hematol Oncol 2015
55
50

SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer.
Nathan A Pennell, Joel W Neal, Jamie E Chaft, Christopher G Azzoli, Pasi A Jänne, Ramaswamy Govindan, Tracey L Evans, Daniel B Costa, Heather A Wakelee, Rebecca S Heist,[...]. J Clin Oncol 2019
109
50

Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry.
J Mazieres, A Drilon, A Lusque, L Mhanna, A B Cortot, L Mezquita, A A Thai, C Mascaux, S Couraud, R Veillon,[...]. Ann Oncol 2019
444
50

Pemetrexed-carboplatin adjuvant chemotherapy with or without gefitinib in resected stage IIIA-N2 non-small cell lung cancer harbouring EGFR mutations: a randomized, phase II study.
Ning Li, Wei Ou, Xiong Ye, Hai-Bo Sun, Liang Zhang, Qin Fang, Song-Liang Zhang, Bao-Xiao Wang, Si-Yu Wang. Ann Surg Oncol 2014
68
50

Afatinib with subsequent surgery in stage III NSCLC with EGFR mutation: Lessons learned from two clinical experiences.
Francesca Mazzoni, Paolo Petreni, Marco Perna, Vieri Scotti, Stefano Bongiolatti, Lorenzo Livi, Francesco Di Costanzo, Luca Voltolini. Tumori 2018
4
50

Global cancer statistics, 2012.
Lindsey A Torre, Freddie Bray, Rebecca L Siegel, Jacques Ferlay, Joannie Lortet-Tieulent, Ahmedin Jemal. CA Cancer J Clin 2015
50

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.
Rafael Rosell, Enric Carcereny, Radj Gervais, Alain Vergnenegre, Bartomeu Massuti, Enriqueta Felip, Ramon Palmero, Ramon Garcia-Gomez, Cinta Pallares, Jose Miguel Sanchez,[...]. Lancet Oncol 2012
50

Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS).
Masahiro Fukuoka, Yi-Long Wu, Sumitra Thongprasert, Patrapim Sunpaweravong, Swan-Swan Leong, Virote Sriuranpong, Tsu-Yi Chao, Kazuhiko Nakagawa, Da-Tong Chu, Nagahiro Saijo,[...]. J Clin Oncol 2011
50

Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.
Jean-Charles Soria, Yuichiro Ohe, Johan Vansteenkiste, Thanyanan Reungwetwattana, Busyamas Chewaskulyong, Ki Hyeong Lee, Arunee Dechaphunkul, Fumio Imamura, Naoyuki Nogami, Takayasu Kurata,[...]. N Engl J Med 2018
50

Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer.
Christian Rolfo, Philip Mack, Giorgio V Scagliotti, Charu Aggarwal, Maria E Arcila, Fabrice Barlesi, Trever Bivona, Maximilian Diehn, Caroline Dive, Rafal Dziadziuszko,[...]. J Thorac Oncol 2021
84
50


Comparison of Sequential Testing and Next Generation Sequencing in advanced Lung Adenocarcinoma patients - A single centre experience.
Filippo G Dall'Olio, Nicole Conci, Giulio Rossi, Michelangelo Fiorentino, Andrea De Giglio, Giada Grilli, Annalisa Altimari, Elisa Gruppioni, Daria M Filippini, Alessandro Di Federico,[...]. Lung Cancer 2020
14
50

Next generation sequencing in cytology.
Pasquale Pisapia, Francesco Pepe, Roberta Sgariglia, Mariantonia Nacchio, Gianluca Russo, Floriana Conticelli, Ilaria Girolami, Albino Eccher, Claudio Bellevicine, Elena Vigliar,[...]. Cytopathology 2021
12
50

Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non-small Cell Lung Cancer.
Natasha B Leighl, Ray D Page, Victoria M Raymond, Davey B Daniel, Stephen G Divers, Karen L Reckamp, Miguel A Villalona-Calero, Daniel Dix, Justin I Odegaard, Richard B Lanman,[...]. Clin Cancer Res 2019
247
50

Somatic and Germline BRCA 1 and 2 Mutations in Advanced NSCLC From the SAFIR02-Lung Trial.
Jordi Remon, Benjamin Besse, Alexandra Leary, Ivan Bièche, Bastien Job, Ludovic Lacroix, Aurélie Auguste, Marjorie Mauduit, Clarisse Audigier-Valette, Judith Raimbourg,[...]. JTO Clin Res Rep 2020
4
50

Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy.
Shumei Kato, Ki Hwan Kim, Hyo Jeong Lim, Amelie Boichard, Mina Nikanjam, Elizabeth Weihe, Dennis J Kuo, Ramez N Eskander, Aaron Goodman, Natalie Galanina,[...]. Nat Commun 2020
84
50

Cost-effectiveness analysis comparing companion diagnostic tests for EGFR, ALK, and ROS1 versus next-generation sequencing (NGS) in advanced adenocarcinoma lung cancer patients.
Luciene Schluckebier, Rosangela Caetano, Osvaldo Ulises Garay, Giuliana T Montenegro, Marcelo Custodio, Veronica Aran, Carlos Gil Ferreira. BMC Cancer 2020
20
50

Molecular testing and targeted therapy for non-small cell lung cancer: Current status and perspectives.
Evgeny N Imyanitov, Aglaya G Iyevleva, Evgeny V Levchenko. Crit Rev Oncol Hematol 2021
85
50

The evolving landscape of biomarker testing for non-small cell lung cancer in Europe.
Keith M Kerr, Frédéric Bibeau, Erik Thunnissen, Johan Botling, Aleš Ryška, Jürgen Wolf, Katarina Öhrling, Peter Burdon, Umberto Malapelle, Reinhard Büttner. Lung Cancer 2021
43
50

Cost of cancer diagnosis using next-generation sequencing targeted gene panels in routine practice: a nationwide French study.
Patricia Marino, Rajae Touzani, Lionel Perrier, Etienne Rouleau, Dede Sika Kossi, Zou Zhaomin, Nathanaël Charrier, Nicolas Goardon, Claude Preudhomme, Isabelle Durand-Zaleski,[...]. Eur J Hum Genet 2018
39
50

Lung Cancer Biomarkers.
Pamela Villalobos, Ignacio I Wistuba. Hematol Oncol Clin North Am 2017
98
50


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.